EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Tocilizumab in refractory pretibial myxedema: new therapeutic insights

Silvia Corrias, Aurora Arba, Filippo Lixi, Giuseppe Giannaccare, Francesco Boi iD, Giulia Lanzolla iD

JCEM Case Reports · 16.10.2026 · 4 (12)

DOI: 10.1210/jcemcr/luag249 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 22.10.2026. Verfasst von Silvia Corrias und 5 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Department of Medical Sciences and Public Health, University of Cagliari, 09042 Monserrato, CA, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pretibial myxedema (PTM) is a rare extrathyroidal manifestation of Graves disease, often associated with Graves orbitopathy (GO). Tocilizumab, an interleukin-6 receptor inhibitor, is effective in refractory GO, but its role in PTM is unclear. We report the case of a 72-year-old woman with longstanding Graves disease who developed glucocorticoid-refractory GO and diffuse glucocorticoid-refractory PTM. Tocilizumab (8 mg/kg intravenously every 4 weeks) was initiated as second-line treatment of moderate to severe active GO. After 6 infusions, the patient experienced a significant improvement in both activity and severity of GO, while PTM showed near-complete resolution of edema and skin induration. No adverse events were recorded. Our findings suggest that interleukin-6 receptor inhibition with tocilizumab may represent a novel therapeutic option for refractory thyroid dermopathy, particularly in the setting of concomitant GO.

Schlagwörter

Stichwörter der Autor:innen

Graves orbitopathyinterleukin-6 receptorpretibial myxedemathyroid dermopathythyroid eye diseasetocilizumab

Autor:innen und Institutionen

  • Endocrinology Unit, Department of Medical Sciences and Public Health, University of Cagliari, 09042 Monserrato, CA, Italy.
  • Ophthalmology Unit, Department of Surgical Sciences, University of Cagliari, 09042 Monserrato, CA, Italy.

ORCID-Profile: Francesco Boi, Giulia Lanzolla

Zitieren

APA

Corrias, S., Arba, A., Lixi, F., Giannaccare, G., Boi, F., & Lanzolla, G. (2026). Tocilizumab in refractory pretibial myxedema: new therapeutic insights. JCEM Case Reports, 4(12). https://doi.org/10.1210/jcemcr/luag249

Vancouver

Corrias S, Arba A, Lixi F, Giannaccare G, Boi F, Lanzolla G. Tocilizumab in refractory pretibial myxedema: new therapeutic insights. JCEM Case Reports. 2026;4(12). doi:10.1210/jcemcr/luag249

BibTeX
@article{Corrias2026,
  author = {Corrias, Silvia and Arba, Aurora and Lixi, Filippo and Giannaccare, Giuseppe and Boi, Francesco and Lanzolla, Giulia},
  title = {Tocilizumab in refractory pretibial myxedema: new therapeutic insights},
  journal = {JCEM Case Reports},
  year = {2026},
  volume = {4},
  number = {12},
  doi = {10.1210/jcemcr/luag249}
}
Kostenlos starten →